

Evidence-Based Studies & Related Dosing Information for Medical Marijuana & Component Parts

last updated: March 2015

General References

- 1) Health Canada. Information for Health Care Professionals. 2013
<http://www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprof-eng.php>
- 2) Koppel BS, Brust JCM, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. *Neurology* 2014;82:1556-1563

Severe Pain

- 1) Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology* 2005;65:812-819.
- 2) Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. *Neurology* 2007;68:515-521.
- 3) Abrams DI, Vizoso HP, Shade SB, et al. Vaporization as a smokeless cannabis delivery system: A pilot study. *Clin Pharmacol Ther.* 2007;82:572-578.
- 4) Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. *Anesthesiology* 2007;107:785-796.
- 5) Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *Journal of Pain* 2008;9:506-521.
- 6) Martin-Sanchez E, Furukawa TA, Taylor J, Martin JLR. Systematic review and meta-analysis of cannabis treatment for chronic pain. *Pain Medicine* 2009;10:1353-1368.
- 7) Ellis R, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. *Neuropsychopharmacology* 2009;34:672-680.
- 8) Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ* 2010;182:E694-701.
- 9) Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Br J Clin Pharmacol.* 2011;72:735-744.
- 10) Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interaction in chronic pain. *Clin Pharmacol Ther.* 2011;90:844-851.
- 11) Wilsey B, Marcotte T, Deutsch R, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. *Journal of Pain* 2012;14:136-148.

Persistent muscle spasms (Multiple Sclerosis)

- 1) Zajicek JP, Fox P, Sanders H, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* 2003;362:1517-1526.
- 2) Vaney C, Heinzl-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. *Mult Scler* 2004;10:417-424.
- 3) Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Mult Scler* 2004;10:434-441.
- 4) Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. *J Neurol Neurosurg Psychiatry* 2005;76:1664-1669.
- 5) Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *Eur J Neurol* 2007;14:290-296.
- 6) Collin C, Ehler E, Waberszinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. *Neurol Res* 2010;32:451-459.
- 7) Zajicek JP, Hobart JC, Slade A, et al; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. *J Neurol Neurosurg Psychiatry* 2012;83:1125-1132.
- 8) Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). *Mult Scler* 2012;18:219-228.
- 9) Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ* 2012;184:1143-1150.

Seizures (Epilepsy)

- 1) Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. *Epilepsy & Behavior* 2013;29:574-577.
- 2) Gloss D, Vickrey B. Cannabinoids for epilepsy. *Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.:CD009270.

Cancer (Chemotherapy-induced nausea and vomiting)

- 1) Ekert H, Waters KD, Jurk IH, et al. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. *Med J Aust.* 1979;2:657-659.

- 2) Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. *N Engl J Med.* 1980;302:135-138.
- 3) Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. *BMJ* 2001;323:16-21.
- 4) Musty R, Rossi R. Effects of smoked cannabis and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. *Journal of Cannabis Therapeutics* 2001;1:29-42.
- 5) Machado Rocha FC, Stefano SC, De Cassia Haiek R, et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *Eur J Cancer Care* 2008;17:431-443.

Cancer (cachexia and anorexia)

- 1) Regelson W, Butler JR, Schulz J. Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. The Pharmacology of marijuana: A monograph of the National Institute on Drug Abuse. Braude M and Szara S. New York: Raven Press, 1976.
- 2) Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. *J Palliat Care* 1994;10:14-18.
- 3) Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. *Oncologist* 2010;15:200-211.

HIV or AIDS (cachexia and anorexia)

- 1) Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *J Pain Symptom Manage.* 1995;10:89-97.
- 2) Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. *J Pain Symptom Manage.* 1997;14:7-14.
- 3) Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection; a randomized, placebo-controlled clinical trial. *Ann Intern Med* 2003;139:258-266.
- 4) Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. *Psychopharmacology* 2005;181:170-178.
- 5) Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers: Caloric intake, mood, and sleep. *J Acquir Immune Defic Syndr.* 2007;45:545-554.

Cachexia

See “Cancer (Cachexia and anorexia)” & “HIV or AIDS (cachexia and anorexia)”

Severe Nausea

See “Cancer (Chemotherapy-induced nausea and vomiting)”

Glaucoma

- 1) Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. *Trans Am Ophthalmol Soc.* 2002;100:215-222.
- 2) Tomida I, Pertwee RG, zuara-Blanco A. Cannabinoids and glaucoma. *Br J Ophthalmol.* 2004;88:708-713.
- 3) Wan MJ, Daniel S, Kassam F, et al. Survey of complementary and alternative medicine use in glaucoma patients. *J Glaucoma* 2012;21:79-82.